Eli Lilly and Company (LLY)
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Eli Lilly Comes Out As ADA Winner
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Favorable commercial trends for tirzepatide and a robust pipeline—including orforglipron and retatrutide—support Lilly's continued market dominance for the next 5-7 years.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
